Cyberonics publishes depression data
This article was originally published in The Gray Sheet
Executive Summary
Results from the firm's pivotal and companion studies are published in the journal Biological Psychiatry, aiding the firm's quest to secure reimbursement for VNS Therapy for treatment-resistant depression. The articles represent the same data used to support the firm's PMA submission for the device, including the firm's 235-patient, 21-site pivotal D-02 study. The firm believes that reimbursement will be in place for the therapy by 2007 (1"The Gray Sheet" July 25, 2005, p. 17)...
You may also be interested in...
Cyberonics Nabs Approval For Depression Device, Plans For Reimbursement
Cyberonics predicts reimbursement for VNS Therapy for treatment-resistant depression (TRD) will be fully secured by 2007, despite encountering protracted difficulties in gaining FDA approval
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.